Expanded Access for IMMU-132

Gilead Sciences

Status

Conditions: Metastatic Triple-Negative Breast Carcinoma

Treatments: Drug: IMMU-132

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT04320693

IMMU-132

Details and patient eligibility

About

This is an expanded access program (EAP) for eligible participants designed to provide access to IMMU-132.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Exclusion criteria